Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025American Journal of Cardiovascular DrugsOpen Access

Cardiovascular Safety of Bruton Tyrosine Kinase Inhibitors: From Ibrutinib to Next-Generation Agents

View Full Paper
Ask AI
Bookmark
Share

Authors

LSLuigi SpadaforaFRFederico RussoEBEwelina Bukowska‐Olech

Discussion

Loading...

Member takes

Overview

Narrative review highlights cardiovascular toxicity of BTKIs in B-cell malignancies, suggesting safer alternatives.

Key Points

  • BTK inhibitors improve survival in chronic lymphocytic leukemia and mantle cell lymphoma, but are linked to cardiovascular toxicity.
  • Evidence shows significant risks such as atrial fibrillation and hypertension associated with first-generation agents like ibrutinib.
  • The review examines mechanisms and risk factors behind BTKI-induced cardiovascular events, advocating for better patient management.
  • Future research should enhance risk stratification models to ensure long-term safety of BTKI therapies among patients.

Cite This Study

Spadafora et al. (2025) studied this question.

synapsesocial.com/papers/68c238d2b210217d64779732https://doi.org/10.1007/s40256-025-00757-6
View Full Paper
Ask AI
Bookmark
Share